Recent News

• 09.09.2025 - Updated Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non-Small Cell Lung Cancer: Phase 2 TRUST-I Study
• 09.09.2025 - Clinical Pharmacologic Characteristics of Taletrectinib
• 09.09.2025 - TRUST-III: Phase 3 Head-to-Head Study of Taletrectinib vs Crizotinib in Patients With ROS1+ Non-Small Cell Lung Cancer (NCT06564324)
• 09.09.2025 - Taletrectinib, a Next-Generation Selective ROS1 Inhibitor, Exhibits a Differentiated Profile in ROS1 Fusion Models
• 09.07.2025 - Updated Efficacy and Safety of Taletrectinib in Patients With ROS1+ Non-Small Cell Lung Cancer: The Global TRUST-II Study

Recent Filings

• 08.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.07.2025 - 8-K Current report
• 08.07.2025 - EX-99.1 EX-99.1
• 07.17.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 06.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.18.2025 - 4 Statement of changes in beneficial ownership of securities